Hormesis and adult adipose-derived stem cells.
Calabrese EJ.
Narrative Review, published in Pharmacol Res (2021) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Pharmacol Res (2021)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 34364988
- DOI
- 10.1016/j.phrs.2021.105803
- Citations
- 21
Abstract (original English)
This paper provides a detailed assessment of the occurrence of hormetic dose responses in adipose-derived stem cells (ADSCs) of animal models and humans. While a broad range of endpoints has been considered, the predominant research focus in the literature has involved cell proliferation and differentiation. Hormetic dose responses have been commonly reported for ADSCs, encompassing a broad range of chemicals, including pharmaceuticals, dietary supplements and endogenous agents as well as a broad range of physical stressors such as low frequency vibrations, electromagnetic frequency (EMF), heat and sound waves. Numerous agents upregulate key functions such as cell proliferation and differentiation in ADSCs, following the quantitative features of the hormesis dose response model. The paper also assesses the capacity of agents to selectively and dose-dependently activate cell proliferation and/or differentiation, their underlying mechanistic foundations and potential clinical implications. These findings indicate that hormetic dose responses are a prominent feature of ADSC biology and may have a determinant role in their potential clinical applications.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.